REG - Celadon Pharma. PLC - Notification of transaction by PDMR

Celadon PharmaceuticalsAnnouncement

10/02/2023 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230210:nRSJ6209Pa&default-theme=true

RNS Number : 6209P  Celadon Pharmaceuticals PLC  10 February 2023

 

Celadon Pharmaceuticals Plc

 

("Celadon" or the "Company")

 

Notification of transactions by persons discharging managerial responsibility

 

London, 10 February 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based
pharmaceutical company focused on the research, cultivation, manufacturing and
sale of breakthrough cannabis-based medicines, announces that an award of
options to acquire the Company's shares for their nominal value of £0.01 was
granted to an Executive Director on 9 February 2023 under the Company's Long
Term Incentive Plan ("LTIP") as shown below.  The Options will vest on the
third anniversary of grant on 9 February 2026, subject to the achievement of
performance criteria.  Once vested, the awards must be held for two years.

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Jonathan Turner
 2   Reason for the notification
 a)  Position / status                                            PDMR - Chief Financial Officer
 b)  Initial notification / Amendment                             Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Celadon Pharmaceuticals plc
 b)  LEI                                                          213800YXCATORT475807
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.01

     Identification code                                          GB00BDQYGP38
 b)  Nature of the transaction                                    Award over nominal cost options under the Celadon Pharmaceuticals plc Long
                                                                  Term Incentive Plan
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  £0.01     347,312 (under the LTIP)
 d)  Aggregated information                                       N/A Single Transaction

     -       Aggregated volume

     -       Price
 e)  Date of the transaction                                      9 February 2023
 f)  Place of the transaction                                     London

d)

Aggregated information

-       Aggregated volume

-       Price

N/A Single Transaction

e)

Date of the transaction

9 February 2023

f)

Place of the transaction

London

 

Enquiries:

 

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Jonathan Turner

 Arthur Wakeley

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Bobbie Hilliam / Andrew Potts / Patrick Dolaghan          +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /             +44 (0)20 7250 1446

 Ibrahim Khalil

 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and sale of breakthrough
cannabis-based medicines. Its primary focus is on improving quality of life
for chronic pain sufferers, as well as exploring the potential of
cannabis-based medicines for other conditions such as autism. Its 100,000 sq.
ft UK facility operates to an EU-GMP standard and comprises indoor hydroponic
cultivation, proprietary GMP extraction and manufacturing and an analytical
and R&D laboratory. The Company's subsidiary, LVL, owns a MHRA
conditionally-approved clinical trial using cannabis based medicinal products
to treat chronic pain in the UK. Celadon also has a minority interest in
early-stage biopharma Kingdom Therapeutics which is developing a licenced
cannabinoid medicine to treat children with Autism Spectrum Disorder.

 

For further information please visit our website www.celadonpharma.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFISFIIILIV